文献速递介入胸部CT

标准化经皮微波消融治疗肺部肿瘤:一项前瞻性多中心试验(MALT研究)

Standardizing percutaneous Microwave Ablation in the treatment of Lung Tumors: a prospective multicenter trial (MALT study).
PubMed 文献 · Eur Radiol · 2020-09-30

该前瞻性多中心试验评估了CT引导下经皮微波消融治疗不可切除的原发性和转移性肺部肿瘤(最大4 cm)的可重复性、安全性和有效性。消融后CT显示消融尺寸较离体牛肝模型小约25%,但消融后1个月治疗区域体积增加40%。无治疗相关死亡或并发症,总局部进展率为24.7%,平均至局部进展时间为8.1个月,12个月和24个月总生存率分别为98.0%和71.3%。

要点

  • 消融后即刻CT显示的消融尺寸较离体牛肝模型系统性小约25%,消融后1个月治疗区域体积增加40%。
  • 总局部进展率为24.7%,平均至局部进展时间8.1个月;12个月和24个月总生存率分别为98.0%和71.3%。

核心结论

  • 经皮CT引导下微波消融是治疗最大4 cm恶性肺肿瘤的可重复、安全且有效的治疗方法。

研究设计与样本

  • 前瞻性多中心临床试验,纳入不可切除的原发性和转移性肺肿瘤(最大4 cm)患者,共54例患者行69次CT引导下微波消融。
  • 治疗采用基于目标肿瘤大小和组织学分类的预设微波功率和持续时间设置,随访长达24个月。
  • 消融体积在CT上测量,并与相同治疗设置的离体牛肝模型消融体积进行比较。

关键影像表现/征象

  • 消融后即刻CT扫描显示消融尺寸较离体模型小约25%,但消融后1个月治疗区域体积增加40%。
  • 相同功率和持续时间的治疗在消融后48小时CT扫描上产生相当可重复的消融尺寸。
  • 与离体牛肝模型相比,在体消融尺寸系统性小约25%。

诊断标准与关键数值

  • 总局部进展率为24.7%,平均至局部进展时间为8.1个月。
  • 12个月和24个月总生存率分别为98.0%和71.3%。
  • 61次操作(88.4%)完成治疗且未偏离标准化方案。

临床应用与阅片要点

  • 使用基于肿瘤组织学和大小的预设治疗持续时间和功率设置时,对于原发性和转移性肿瘤,局部进展率不随肿瘤大小(最大4 cm)增加而增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To prospectively assess reproducibility, safety, and efficacy of microwave ablation (MWA) in the treatment of unresectable primary and secondary pulmonary tumors.

METHODS: Patients with unresectable primary and metastatic lung tumors up to 4 cm were enrolled in a multicenter prospective clinical trial and underwent CT-guided MWA. Treatments were delivered using pre-defined MW power and duration settings, based on target tumor size and histology classifications. Patients were followed for up to 24 months. Treatment safety, efficacy, and reproducibility were assessed. Ablation volumes were measured at CT scan and compared with ablation volumes obtained on ex vivo bovine liver using equal treatment settings.

RESULTS: From September 2015 to September 2017, 69 MWAs were performed in 54 patients, achieving technical success in all cases and treatment completion without deviations from the standardized protocol in 61 procedures (88.4%). Immediate post-MWA CT scans showed ablation dimensions smaller by about 25% than in the ex vivo model; however, a remarkable volumetric increase (40%) of the treated area was observed at 1 month post-ablation. No treatment-related deaths nor complications were recorded. Treatments of equal power and duration yielded fairly reproducible ablation dimensions at 48-h post-MWA scans. In comparison with the ex vivo liver model, in vivo ablation sizes were systematically smaller, by about 25%. Overall LPR was 24.7%, with an average TLP of 8.1 months. OS rates at 12 and 24 months were 98.0% and 71.3%, respectively.

CONCLUSIONS: Percutaneous CT-guided MWA is a reproducible, safe, and effective treatment for malignant lung tumors up to 4 cm in size.

KEY POINTS: • Percutaneous MWA treatment of primary and secondary lung tumors is a repeatable, safe, and effective therapeutic option. • It provides a fairly reproducible performance on both the long and short axis of the ablation zone. • When using pre-defined treatment duration and power settings according to tumor histology and size, LPR does not increase with increasing tumor size (up to 4 cm) for both primary and metastatic tumors.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Iezzi R, Cioni R, Basile D, et al. Standardizing percutaneous Microwave Ablation in the treatment of Lung Tumors: a prospective multicenter trial (MALT study). Eur Radiol. 2020. PMID: 32997180. doi:10.1007/s00330-020-07299-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。